capivasertib plus fulvestrant for patients with metastatic hormone-positive breast cancer
Published 2 years ago • 197 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
5:28
capitello-291: capivasertib fulvestrant for ai-resistant hr /her2- advanced breast cancer
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
2:27
capivasertib fulvestrant improves progression-free survival in advanced hr breast cancer patients
-
3:27
alpelisib plus fulvestrant for hormone receptor positive metastatic breast cancer
-
2:15
capivasertib in advanced breast cancer | nejm
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
0:58
results of capitello291 - capivasertib
-
0:52
background on capivasertib - now approved for breast cancer
-
6:17
tesetaxel plus reduced-dose capecitabine among patients with hr /her2- metastatic breast cancer
-
1:18
the significance of fulvestrant for hormone receptor-positive advanced breast cancer
-
21:42
dr. hope rugo discusses capivasertib fda approval based on capitello-291 study
-
3:27
tesetaxel plus capecitabine for patients with metastatic breast cancer
-
1:21
fda approves truqap (capivasertib) faslodex for patients with advanced hr-positive breast cancer
-
1:18
fda approves truqap (capivasertib) faslodex for patients with advanced hr-positive breast cancer..
-
2:02
palbociclib combined with fulvestrant in relapsed metastatic hr /her2- breast cancer
-
4:07
capivasertib for akt1 e17k-mutated metastatic including breast cancer: nci-match eay131-y
-
14:02
approval of capivasertib for pik3ca/akt1/pten–altered breast cancer: jason mouabbi and carlos doti
-
0:55
fulvestrant plus palbociclib in breast cancer
-
6:20
fulvestrant and palbociclib as first-line treatment for hr /her2- breast cancer